Market Performance - Major stock indices in China saw significant gains, with the North China 50 Index rising over 1% to reach a new high [1] - The FTSE China A50 Index futures increased by more than 1%, while the offshore RMB appreciated by 101 points against the USD, currently at 7.2041 [2] - The Shanghai Composite Index closed up 0.38% at 3393.49 points, with the Shenzhen Component Index up 0.53% and the ChiNext Index up 0.99% [2] Sector Highlights - The coal sector showed strong performance, with companies like Dayou Energy and Jinkong Coal Industry hitting the daily limit, and Shanmei International rising nearly 6% [2] - The solid-state battery concept gained traction, with companies like Lingpai Technology and Ningde Times seeing significant price increases, with Lingpai Technology hitting a 20% limit up [2][4] - The innovative drug sector remained active, with Shuyitai and SanSheng Guojian both hitting the daily limit, and SaiSheng Pharmaceutical rising over 12% [7] Company Developments - Ningde Times, which recently listed on the Hong Kong Stock Exchange, saw its stock rise by over 9% during trading [3] - Bubble Mart reached a new historical high, with its stock price rising over 5% to 220 HKD per share, bringing its market capitalization close to 300 billion HKD [10] - Bubble Mart's Labubu 3.0 product has gained immense popularity globally, leading to long queues in stores and significant price premiums on secondary markets [12] Industry Trends - The solid-state battery sector is identified as a core focus within the lithium battery industry, with companies actively launching new products and materials seeing increased demand [6] - The innovative drug market in China is projected to grow from 132.5 billion USD in 2019 to 159.2 billion USD by 2024, maintaining a global market share of around 15% [9]

哈三联再度涨停，5个交易日内录得3个涨停，累计涨幅为32.26%，累计换手率为124.31%。截至10:03， 该股今日成交量3136.53万股，成交金额4.50亿元，换手率18.12%。最新A股总市值达48.12亿元，A股流 通市值26.33亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，机构净卖出1986.53万元，营业部席位合计净买入842.36万元。 （文章来源：证券时报网） 4月25日公司发布的一季报数据显示，一季度公司共实现营业总收入2.05亿元，同比下降16.93%，实现 净利润-0.29亿元，同比下降253.52%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.05.20 | -3.49 | 26.67 | 83.24 | | 2025.05.19 | 2.95 | 34.47 | -2848.61 | | 2025.05.16 | 10.04 | 31.34 | -2453.79 | | 2025.05.15 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

证券代码：002900 证券简称：哈三联 公告编号：2025-029 哈尔滨三联药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协 议等；公司董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》等有 关规定应予以披露而未披露的、对本公司股票交易价格产生较大影响的信息；公 司前期披露的信息不存在需要更正、补充之处。 一、股票交易异常波动的情况介绍 哈尔滨三联药业股份有限公司（以下简称"公司"或"本公司"）（证券代码： 002900，证券简称：哈三联）股票连续 2 个交易日内（2025 年 5 月 15 日、2025 年 5 月 16 日）日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交 易规则》的相关规定，属于股票交易异常波动情况。 二、公司关注并核实情况的说明 针对公司股票交易的异常波动，公司董事会对公司、控股股东及实际控制人 就相关事项进行了核实，现就有关情况说明如下 ...

Market Overview - As of May 16, the Shanghai Composite Index closed at 3367.46 points, down 13.36 points, a decrease of 0.40% [1] - The Shenzhen Component Index closed at 10179.60 points, down 6.85 points, a decrease of 0.07% [1] - The ChiNext Index closed at 2039.45 points, down 3.80 points, a decrease of 0.19% [1] Stock Performance - A total of 113 A-shares had a turnover rate exceeding 20% on this day, indicating significant trading activity [1] - Notable stocks with high turnover rates included: - C Zairun (301636) with a turnover rate of 79.01% and a price increase of 99.52% [1] - C Hanbang (688755) with a turnover rate of 75.65% and a price increase of 102.46% [1] - Ningbo Yuanyang (601022) with a turnover rate of 67.73% and a price increase of 9.98% [1] - Tian Gong Co. (920068) with a turnover rate of 53.83% and a price decrease of 7.78% [1] - Bawei Co. (837023) with a turnover rate of 50.87% and a price decrease of 12.12% [1] Additional Notable Stocks - Other stocks with significant turnover rates included: - Hongqiang Co. (002809) at 49.79% with a price increase of 9.99% [1] - Huafang Co. (600448) at 49.78% with a price decrease of 2.10% [1] - Huaguang Yuanhai (872351) at 46.17% with a price decrease of 11.43% [1] - Jinjiang Shipping (601083) at 41.68% with a price decrease of 8.89% [1] - Zhongzhou Special Materials (300963) at 41.61% with a price increase of 20.00% [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-028 哈尔滨三联药业股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： （1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东。 一、会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 5 月 15 日（周四）15:30； （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 15 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 5 月 15 日 9:15-15:00 期间任意时间。 1、本次股东大会无否决议案或修改议案的情况；本次股东大会上无新提议 案提交表决； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会因涉及审议影响中小投资者利益的重大事项，公司将对中小 投资者表决情况进行单独计票。中小投资者是指以下股东以外的其他股东： 2、 ...

法律意见书 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2024 年年度股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2024 年年度股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）》《上市公司股东会规则》等相关法律、法规、规范性文件 及《哈尔滨三联药业股份有限公司章程》（以下简称"《公司章程》"）的规定， 对本次股东大会进行见证并出具法律意见。 1 法律意见书 即其已提供了本所律师认为作为出具本法律意见书所必需的材料，所提供的原始 材料、副本、复印件等材料、口头证言均符合真实、准确、完整的要求，有关副 本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 等法律、法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的议 案内 ...

Market Overview - The market experienced a volume contraction with the ChiNext index dropping nearly 2% by the end of the day. The synthetic biology concept stocks surged, with companies like Chuaning Biological, Jieya Co., and Meinong Biological hitting the daily limit. The shipping sector saw a rise and subsequent fall, with Ningbo Shipping, Ningbo Ocean, and Lianyungang achieving three consecutive limits. Consumer stocks in food, apparel, and beauty care were active, with Xiwang Food, Lafang Cosmetics, and Fengzhu Textile also hitting the daily limit. Conversely, the military industry faced adjustments, with Tianjian Technology nearing a limit down, and computing power concept stocks weakened, with Hongjing Technology dropping nearly 10%. Overall, over 3,800 stocks in the Shanghai and Shenzhen markets declined, with a total transaction volume of 1.19 trillion [1]. Hot Topics Health Products - Kolun Pharmaceutical's advertisement for ergothioneine capsules has sparked significant discussion, with Chairman Liu Gexin personally endorsing the product. Ergothioneine is a natural small molecule derived from histidine thiourea, found in microbial cells and plants. It cannot be synthesized by the human body and must be obtained through diet, with mushrooms being a key source. Sales of oral beauty products containing ergothioneine on a major e-commerce platform surged by 60 times year-on-year in the first half of 2024 [4][5]. Shipping - The shipping sector remained active, with Ningbo Ocean and Lianyungang achieving three consecutive limits. Following trade negotiations between China and the U.S., container shipping bookings from China to the U.S. surged nearly 300%, with the average booking volume for 20-foot standard containers skyrocketing to 21,530, up from 5,709 a week prior. Goldman Sachs anticipates a significant increase in Chinese exports over the next 90 days due to a tariff suspension [6][8]. Consumer Sector - The consumer sector was lively, with stocks like Marubi, Dengkang Dental, and Baiyang hitting the daily limit. The Tmall 618 promotion commenced, with the first hour's GMV for popular beauty products increasing over 10% year-on-year. Additionally, the price of tilapia has risen to 4.5 yuan per pound, with China being a major producer and exporter of tilapia, producing over 1.6 million tons annually, with about a quarter exported to the U.S. [9][10]. Stock Performance - Notable stocks in the health products sector include: - Jiaoda Aongli (600530.SS) with a price of 7.50, up 9.97%, and a market cap of 5.812 billion - Lafang Cosmetics with a price of 21.97, up 10.02%, and a market cap of 4.948 billion - Chuaning Biological with a price of 14.02, up 20.03%, and a market cap of 8.635 billion [5][10]. - In the shipping sector: - Ningbo Ocean (601022.SS) at 11.12, up 9.99%, with a market cap of 2.765 billion - Lianyungang (601008.SS) at 6.77, up 10.08%, with a market cap of 8.399 billion [7][10]. - In the consumer sector: - Zhejiang Yongqiang (002489.SZ) at 4.07, up 10.00%, with a market cap of 7.786 billion - Marubi (603983.SS) at 52.53, up 10.01%, with a market cap of 21.065 billion [10].

暗盘资金正涌入这些股票，点击速看>>> 创新药板块拉升，哈三联（002900）涨停，万邦医药（301520）涨超10%，九芝堂（000989）、科伦药 业（002422）、凯莱英（002821）纷纷拉升。 ...

证券代码： 002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活 | □特定对象调研 □ 分析师会议 | | □ 现场参观 | | --- | --- | --- | --- | | 动类别 | □ 媒体采访 | √ 业绩说明会 | □ 其他 | | | □ 新闻发布会 | □ 路演活动 | | | 参与单位名称 | 关于参加黑龙江辖区上市公司 年投资者网上集体接待日活动暨业 | 2025 | | | 及人员姓名 | 绩说明会，投资者网上提问。 | | | | 时间 | 2025 年 5 月 14 日（周三）下午 14:00~16:30 | | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 公司接待人员 | 1、董事、副总裁兼董事会秘书梁延飞先生 | | | | 姓名 | 2、财务总监赵志成先生 | | | | | 1、公司医美产业发展如何？有没有特色优势产品？ | | | | | 尊敬的投资者您好：公司大健康板块目前包括化妆品、医用敷料、 | | | | | "好好"系列纳米乳化饮 ...